BerGenBio ASA: New share capital registered
Bergen, Norway, 25 April 2024 - Reference is made to the stock exchange announcement by BerGenBio ASA (the "Company") on 16 April 2024 regarding the final results of the last exercise period for the warrants ("Warrants") issued in connection with the rights issue, which resulted in an allocation of 1,106,565,434 new shares in the Company ("New Shares") to investors holding Warrants. A reference is also made to the stock exchange announcement by BerGenBio ASA on 17 April 2024 regarding an increase of the Company's share capital by issuance of 113,456,919 new shares in connection with settlement of underwriting commission in accordance with underwriting agreements dated 1 April 2024 and made by and between the Company and the underwriters (the "Fee Shares").
The share capital increases pertaining to the New Shares and the Fee Shares are now registered with the Norwegian Register of Business Enterprises. After this, the Company's new registered share capital is NOK 390,871,156.70 divided into 3,908,711,567 shares, each with a nominal value of NOK 0.10.
For further information, please contact:
Martin Olin CEO, BerGenBio ASA
Rune Skeie, CFO, BerGenBio ASA
About BerGenBio ASA
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate bemcentinib a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit www.bergenbio.com.
This information is published in accordance with the requirements of the Oslo Rule Book II and is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.